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Conclusion: Within the limits of retrospective analysis primary lung 
cancer is a more common form of lung cancer in this review.The com-
monest histological type being adenocarcinoma. 
Late presentation with extensive disease and a large diagnostic time 
was observed from admission to working up the patient and commenc-
ing treatment /death. 
There is a great need for training of physicians in diagnostic procedures 
and treatment of lung cancer in resource poor countries. Smoking either 
actively or passively should be discouraged. 
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Fiberoptic bronchoscopy is standard endoscopic procedure in staging 
of carcinoma of the esophagus. In the bronchoscopy department of our 
Institute more than 3800 bronchoscopies are completed annualy. In the 
2005 to 2006 bronchoscopic staging of carcinoma of the esophagus was 
performed in 141 patients: 120 male 21 female. Normal endoscopic 
appearance existed in 105, direct signs of tumor in 21 and indirect signs 
in 14 patients. One patient had esophagobronchial ﬁstula. Inﬁltration 
of mucosa was established in 14, tumorous vegetation in 7 patients. 
In the group of patients with direct signs, squamocellular carcinoma 
was found in 13 patients. Localisation of direct signs of tumor: trachea 
in 7, main bronchi in 6 and lobar bronchi in 8 patients. Indirect signs 
were present in trachea in 8, main bronchi in 3 and lobar bronchi in 3 
patients. Fiberoptic bronchoscopy is inevitable diagnostic procedure 
in staging of esophageal cancer, which is safe, precise and easily ap-
plicable. It should be done in all patients with this malignancy. Indirect 
signs should be interpreted with caution, as some of them doesn’t 
contraindicate the operation
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Background: Pleurodesis is the treatment of choice for malignant 
pleural effusions. In study populations, talc seems to ensure effective 
pleurodesis in up to 95% of cases. However, data on patient selection, 
decision rules before and during the drainage procedure and effectivity 
score are not always included in published papers on pleurodesis. In the 
Netherlands, the national guideline “Malignant pleurisy”, published in 
2003, recommended e.g. to perform a diagnostic pleurocentesis before 
to proceed to pleurodesis and to perform a talc pleurodesis when the 
lung is completely aligned to the thoracic wall. In this study we mea-
sured the compliance to the guideline and the effectiveness of pleurode-
sis in current practice.
Methods: In four hospitals, all patients with (suspected) malignant 
pleurisy who were drained with the intention to perform a pleurodesis, 
were prospectively registrered. Diagnostic procedures, decision making 
during the drainage and outcome were monitored and compared to the 
guideline.
Results: We prospectively followed 100 patients from February 1st to 
November 30, 2006. All patients had a histologically or cytologically 
conﬁrmed malignancy. LDH, pH and protein levels in pleural ﬂuid 
were known in 84, 75 and 68% respectively before drainage or were 
determined during the procedure as recommended in the guideline. 
Malignant pleurisy was conﬁrmed cytologically in 58 patients, histo-
logically in 5 and was clinically suspected in 35 patients. In 75 patients 
a pleurodesis was performed. Reasons for not performing a pleurodesis 
were trapped lung in 15 patients, high ﬂuid production in 3, alternative 
diagnosis or unable to obtain a cytologic conﬁrmation of the diagnosis 
in 6 patients. Pleurodesis was performed with 2, 3 or 5 gr talc slurry at 
a median interval of 3 days (range 0 - 15 days) after start of the drain-
age. The drain was removed after 5 days (range 2 - 21 days) in case of 
pleurodesis and after 4 days (range 0-9 days) when no pleurodesis was 
performed. A recurrence of pleural ﬂuid was seen in 27 patients (36%), 
with a mean of 17 days after pleurodesis (range 2-285 days); in 11 
(14%) patients no radiological follow up was performed; 14 out of 44 
patients who had pleurodesis and no documented recurrence of pleural 
ﬂuid died during follow up with a median survival of 61 days (range 13 
- 174 days). The most frequently reported side effect during drainage 
was local pain. Ten late complications were reported: one empyema 
and one tumor growth into the scar of the drain were the most severe.
Conclusions: Compared to literature data, pleurodesis seems con-
siderably less effective in general practice. Parameters predicting the 
success rate of pleurodesis are not always known and do not affect 
clinical decision making. Future studies should focus on proper selec-
tion of patients for drainage and pleurodesis. Guidelines should also 
include alternative treatment options such as chronic indwelling pleural 
catheters.
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Bevacizumab is the ﬁrst anti-angiogenic agent inhibiting vascular 
endothelial growth factor (VEGF) for treatment of patients suffering 
from cancer. Life-threatening hemoptysis is the most serious adverse 
effect of bevacizumab. The inhibition of VEGF is a possible mecha-
nism involved in the destruction of normal lung tissue and subsequent 
hemoptysis. We report a case of bevacizumab-related hemoptysis and 
associated bronchoscopic ﬁndings that were successfully treated with 
rigid bronchoscopy and laser photocoagulation.
